NextWave Peptides has announced a U.S.-based research peptide catalog organized around a lot-matched COA library and a stated 99%+ purity standard. The announcement is a company press release, and it does not name the third-party lab or say how much of the catalog the documentation covers.
IBio says an eight-week study in obese nonhuman primates found lean mass made up 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone. The company reported a 33.2-day half-life in monkeys and expects first-in-human trials in the first half of 2027.
AgelessRx has launched a prescription copper peptide cream in 0.5% and 3% strengths, compounded by licensed U.S. pharmacies and priced from $99 a month. The company reports 99.8% purity testing, but no clinical trial of the formulation is cited in the announcement.
A Women's Health feature reports that GLP-1 muscle loss warnings have outpaced the evidence, because the studies behind them measured lean body mass rather than muscle itself. A small new study found thigh muscle shrank slightly in 10 men on semaglutide while their strength stayed the same.
NextWave Peptides says it is restructuring its catalog so product information and lot specific Certificates of Analysis stay connected but distinct, and states a 99%+ purity standard with third party testing. Every figure in the announcement comes from the company itself, and no testing laboratory is named.
Pete Davidson told Variety he used BPC-157 and Sermorelin to gain fifteen pounds of muscle for an upcoming film, and Futurism reports the admission lands in a booming grey market. A cited Wired investigation found one product sold as BPC-157 contained none of it.
An RTE report examines the social media boom in self-administered peptide injections and the near-total absence of human trials behind the claims. An endocrinologist calls the biochemistry sound but says it is far too early to use these substances in people.
Umbrella Labs says it has standardized naming, identity fields, and batch traceability for its MOTS-C research material, with no biological claims attached. The announcement is a procurement story rather than a science one, and the company says the material's research-use-only scope is unchanged.
An NIH-funded study reported that semaglutide extended median lifespan by nearly 100 days in older mice and outperformed calorie restriction on memory and metabolic measures. The researchers say the findings do not show that GLP-1 drugs can extend human lifespan.
Karnataka's drug regulator served notice on a Bengaluru "peptide party" featuring peptide tastings, and the event was canceled. Doctors quoted in the report warn that approved peptide medicines and experimental compounds sold online are not the same category.
A review in High Blood Pressure & Cardiovascular Prevention argues that lean mass lost during GLP-1 weight loss may reflect adaptation to reduced mechanical loading rather than pathological muscle wasting. The authors propose testable predictions but present no new patient data.
The FDA had logged 990 adverse-event reports tied to compounded semaglutide and more than 730 involving compounded tirzepatide as of the end of May, WBAY reports. Experts quoted say online availability of unapproved peptide products is being mistaken for legality.
A Racine County Eye guide lists seven peptides discussed in relation to post-menopausal biology, from FDA-approved tesamorelin to Epithalon, whose human literature is decades old and largely unreplicated. It also quotes clinicians warning that mechanism is not the same as human safety data.
The Australian Drug Foundation's new peptides explainer separates TGA-approved prescription medicines from the unapproved injectables sold online, and puts hard numbers on the gap. Testing of three retatrutide products found content ranging from half to nearly double the labeled dose.
Providers in the Charleston area told WCSC that marketing for peptides is running ahead of the clinical evidence, particularly for compounds sold outside FDA-approved channels. They said the approved GLP-1 drugs carry long-term safety data that many other peptides do not.
Three recent studies touch on semaglutide, and none of them involved human participants. Here is what each one actually reported, and what the authors said still needs testing.
A mouse study in Science Advances reports that TOFA, an ACC inhibitor first discovered in the 1970s, increased energy expenditure by as much as 18% and reduced body fat without significant lean muscle loss. The work was done entirely in animals, and the researchers say safety and effectiveness in humans remain unknown.
